Dario Announces Pricing of a $23.5 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules
Rhea-AI Summary
DarioHealth (NASDAQ: DRIO) has priced a registered direct offering of 3,454,559 shares of common stock (or equivalents) at $6.80 per share, structured as an at-the-market transaction under Nasdaq rules. Expected gross proceeds are approximately $23.5 million before placement fees and expenses, with closing targeted on or about July 23, 2026 subject to customary conditions.
A member of the board of directors is participating by purchasing 14,430 shares at $6.93 per share. According to DarioHealth, net proceeds are intended for working capital, investments, acquisitions and general corporate purposes. The securities are being issued off an effective Form S-3 shelf registration (File No. 333-294454), with A.G.P./Alliance Global Partners acting as sole placement agent. The company highlights participation from existing long-term institutional investors alongside a new global fundamental institutional investor.
Positive
- $23.5 million expected gross proceeds to strengthen liquidity
- Participation from existing and new institutional investors supports capital access
- Board member buying 14,430 shares aligns insider with shareholders
Negative
- Issuance of 3,454,559 new shares increases share count and may dilute holders
- Gross proceeds of $23.5 million are before placement fees and expenses
News Explained
The $23.5 million gross raise would add shares and dilute existing ownership, and exceeds cash reported at March 31, 2026.
DarioHealth has entered agreements to issue 3,454,559 shares or equivalents for expected gross proceeds of
A registered direct offering is a negotiated sale to selected investors, and placement-agent fees reduce net proceeds; the release identifies A.G.P./Alliance Global Partners as sole placement agent.
Using first-quarter operating cash flow as a benchmark, the
The next checkpoints are the expected
Sources and calculations
- Dario Announces Pricing of a $23.5 Million Registered Direct Offering (2026-07-22)
- Dilution (undated)
- Registered direct offering (undated)
- Prospectus supplement purpose (undated)
- DarioHealth first-quarter 2026 fundamentals (2026Q1)
- Offering gross vs quarterly operating cash outflow, in days of cash use $23,500,000 / ($6,025,000 / 90) = [object Object]
- Cash and equivalents vs quarterly operating cash outflow, in days of cash use $14,977,000 / ($6,025,000 / 90) = [object Object]
Market reaction after registered direct offering: DRIO +12.86% in the Jul 22 session
In the Jul 22 session, DRIO gained 12.86%, reflecting a significant positive market reaction. Argus tracked a peak move of +9.6% during that session. Our momentum scanner triggered 12 alerts that day, indicating notable trading interest and price volatility. Trading volume was exceptionally heavy at 12.4x the daily average, suggesting very strong buying interest.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jul 16 | Fortune 50 contract | Positive | +0.3% | Fortune 50 employer awarded Dario a cardiometabolic care platform contract |
| Jul 13 | AI revenue outlook | Positive | -7.2% | Dario projected recurring revenue growth from broader DarioIQ deployment |
| Jul 06 | Insurer partnership | Positive | -1.5% | Arizona health insurer agreement expanded access through Amwell partnership |
| Jul 02 | Health plan expansion | Positive | +7.8% | Major health plan extended its agreement and added hypertension care |
| Jun 30 | Advisory board appointment | Positive | -2.9% | Former Humana compliance chief joined Dario's Advisory Board |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent positive announcements produced mixed outcomes, with three divergences and two alignments between announcement sentiment and 24-hour price reactions.
Key Terms
registered direct offering financial
at-the-market financial
Form S-3 regulatory
shelf registration statement regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
The financing was led by continued support of existing long-term institutional investors along with participation from a new global fundamental institutional investor
The closing of the offering is expected to occur on or about July 23, 2026, subject to the satisfaction of customary closing conditions. The Company intends to use the net proceeds from the offering for working capital, investments, acquisitions, and general corporate purposes.
The Offering was priced at-the-market under Nasdaq rules. Existing long-term Dario institutional investors are participating alongside new fundamental investors, reflecting continued support for the Company's strategic direction and ongoing business transformation into an AI-powered platform for the management of multiple chronic conditions.
A.G.P./Alliance Global Partners is acting as the sole placement agent for the offering.
The securities described above are being offered pursuant to an effective shelf registration statement on Form S-3 (File No. 333-294454) which became effective on March 27, 2026. The Offering is being made only by means of a prospectus which is part of the effective registration statement. A prospectus supplement and the accompanying prospectus relating to the Offering will be filed with the Securities and Exchange Commission (the "SEC") and will be available on the SEC's website located at http://www.sec.gov. Additionally, when available, electronic copies of the prospectus supplement and the accompanying prospectus may be obtained, when available, from A.G.P./Alliance Global Partners, 590 Madison Avenue, 28th Floor,
This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation, or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.
About DarioHealth Corp. (NASDAQ: DRIO)
DarioHealth Corp. (NASDAQ: DRIO) is an AI-powered healthcare technology company helping health plans, health systems and employers improve health outcomes while lowering the cost of care. The Company's integrated platform combines connected devices, personalized member engagement, AI-driven insights and provider-backed clinical care to support people living with conditions including diabetes, hypertension, weight management, musculoskeletal and behavioral health needs.
Powered by more than 13 billion proprietary longitudinal healthcare data points collected over more than a decade, Dario's AI platform personalizes care at the individual member level by analyzing biometric, clinical and behavioral data to deliver more timely and effective interventions. By combining engagement, clinical intelligence and care delivery within a single platform, Dario helps customers address multiple chronic conditions through one solution.
Cautionary Note Regarding Forward-Looking Statements
This news release and the statements of representatives and partners of DarioHealth Corp. related thereto contain or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are not statements of historical fact may be deemed to be forward-looking statements. For example, the Company is using forward-looking statements in this press release when discussing the expected timing of the closing of the offering and the expected use of proceeds. Without limiting the generality of the foregoing, words such as "plan," "project," "potential," "seek," "may," "will," "expect," "believe," "anticipate," "intend," "could," "estimate" or "continue" are intended to identify forward-looking statements. Readers are cautioned that certain important factors may affect the Company's actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect the Company's results include, but are not limited to, regulatory approvals, product demand, market acceptance, impact of competitive products and prices, product development, commercialization or technological difficulties, the success or failure of negotiations and trade, legal, social and economic risks, and the risks associated with the adequacy of existing cash resources. Additional factors that could cause or contribute to differences between the Company's actual results and forward-looking statements include, but are not limited to, those risks discussed in the Company's filings with the U.S. Securities and Exchange Commission. Readers are cautioned that actual results (including, without limitation, the timing for and results of the Company's commercial and regulatory plans for Dario™ as described herein) may differ significantly from those set forth in the forward-looking statements. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.
DarioHealth Corporate Contacts
Michael Lipari
SVP Corporate Development
irteam@dariohealth.com
+1-201-785-6310
Rob Halpern
SVP Marketing
irteam@dariohealth.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/dario-announces-pricing-of-a-23-5-million-registered-direct-offering-of-common-stock-priced-at-the-market-under-nasdaq-rules-302832102.html
SOURCE DarioHealth Corp.